Artivion, Inc.

NYSE AORT

Artivion, Inc. Free Cash Flow Yield on January 14, 2025: 0.29%

Artivion, Inc. Free Cash Flow Yield is 0.29% on January 14, 2025, a -80.69% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Artivion, Inc. 52-week high Free Cash Flow Yield is 1.61% on February 07, 2024, which is 466.32% above the current Free Cash Flow Yield.
  • Artivion, Inc. 52-week low Free Cash Flow Yield is -0.10% on September 11, 2024, which is -136.49% below the current Free Cash Flow Yield.
  • Artivion, Inc. average Free Cash Flow Yield for the last 52 weeks is 0.39%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
NYSE: AORT

Artivion, Inc.

CEO Mr. James Patrick Mackin
IPO Date Feb. 12, 1993
Location United States
Headquarters 1655 Roberts Boulevard N.W.
Employees 1,500
Sector Health Care
Industries
Description

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Similar companies

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

ANIK

Anika Therapeutics, Inc.

USD 15.58

-2.14%

NPCE

NeuroPace, Inc.

USD 11.84

-2.23%

SGHT

Sight Sciences, Inc.

USD 3.15

-2.78%

AXGN

AxoGen, Inc.

USD 18.24

-0.06%

SRDX

Surmodics, Inc.

USD 35.55

-0.81%

CVRX

CVRx, Inc.

USD 16.15

7.38%

CNMD

CONMED Corporation

USD 67.79

-2.46%

SIBN

SI-BONE, Inc.

USD 15.70

-3.27%

ELMD

Electromed, Inc.

USD 31.05

1.90%

AVNS

Avanos Medical, Inc.

USD 15.83

0.19%

ESTA

Establishment Labs Holdings Inc.

USD 33.15

-1.66%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

TMCI

Treace Medical Concepts, Inc.

USD 8.01

-4.19%

LUNG

Pulmonx Corporation

USD 6.84

-2.98%

StockViz Staff

January 15, 2025

Any question? Send us an email